Summary
• Ultragenyx Pharmaceutical Inc. (RARE) shares fell 41.5% to $20.01 after failed Phase 3 trial results for Setrusumab.
• The ORBIT and COSMIC trials did not meet their primary endpoints, leading to a surge in trading volume to over 5.7 million shares.
• Despite the decline, analysts maintain a “Buy” rating, though the company’s recent earnings report showed a larger-than-expected loss of $1.81 per share.
Ultragenyx Pharmaceutical Inc. (RARE) is experiencing a steep decline of 41.5% in intraday trading, with the current price hitting $20.01. This significant drop follows the company’s announcement regarding the outcomes of two Phase 3 studies for its product Setrusumab (UX143) in treating Osteogenesis Imperfecta, which failed to achieve its primary endpoint related to clinical fracture rate reduction.
Trial Results Weigh Heavy on Investor Sentiment
On December 29, 2025, Ultragenyx revealed that neither the ORBIT nor the COSMIC trials met their respective main objectives. The ORBIT study aimed to demonstrate a reduction in annualized clinical fracture rates compared to placebo, and the COSMIC study compared the treatment with bisphosphonates. The disappointing results have left investors unsettled, sparking a heavy sell-off in the stock.
Adding to the context, RARE’s trading volume has surged to over 5.7 million shares today, significantly above its average volume of 1.4 million shares over the past three months. This heightened trading activity often reflects a response to major news events or changes in market sentiment.
Performance Metrics Illustrate Ongoing Challenges
The impact of today’s price movement reflects broader challenges for RARE, which has faced a -21.4% decline over the past year. Despite a quarterly performance improvement of 22.9%, the yearly and year-to-date (YTD) performances remain negative at -21.4% and -18.7%, respectively. The stock also recently reached a 52-week low, contrasting sharply with its high of $32.47.
A closer examination of the technical indicators shows an RSI of 49.3, suggesting that the stock is moving into neutral territory, while the ATR is at 1.38, indicating moderate volatility. The SMA indicators vary: the 20-day SMA shows a -2.3% deviation, while the 50-day and 200-day SMAs reflect slight positive deviations of 0.8% and 2.1%.
Analyst Sentiment and Market Dynamics
Analysts maintain a “Buy” rating on RARE, despite the setbacks associated with the recent trial outcomes. This could indicate that some investors still see potential in the company’s pipeline and long-term prospects. However, today’s sharp decline may have caused a reevaluation of that outlook as the realities of drug development weigh heavily on stock performance.
According to the most recent earnings information, the company reported a surprise loss of $1.81 per share compared to an estimate of a loss of $1.23, contributing further to investor unease.
As RARE navigates through these turbulent conditions, it will be crucial for the company to reassess its strategy and focus on pipeline enhancements to restore confidence among shareholders.
With shares experiencing a significant downturn in response to the latest clinical results, investor sentiment remains cautious as the company seeks to recover from these clinical setbacks.